Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer

@inproceedings{Tagawa2013BoneMR,
  title={Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer},
  author={Scott T. Tagawa and Naveed Hassan Akhtar and Anastasia Nikolopoulou and Gurveen Kaur and Brian Robinson and Ren{\'e}e S Kahn and S. Vallabhajosula and Stanley J. Goldsmith and David M. Nanus and Neil Harrison Bander},
  booktitle={Front. Oncol.},
  year={2013}
}
Radioimmunotherapy (RIT) has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin's lymphoma, but has been slower to develop for the treatment of advanced solid tumors. Prostate cancer (PC) represents a good candidate for RIT based upon high exposure to circulating antibodies at common disease sites with a specific, highly… CONTINUE READING